Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump p-glycoprotein

Inflammatory Bowel Diseases

Volumn 10, Issue 5, 2004, Pages 578-583

  Dilger, Karin ^a   Schwab, Matthias ^b   Fromm, Martin F ^b,c  

^a Dr Falk Pharma GmbH   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Budesonide; Crohn's disease; MDR1; P glycoprotein; Prednisone

Indexed keywords

BUDESONIDE; COMPLEMENTARY DNA; CORTICOSTEROID; DIGOXIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISONE; STEROID; TRITIUM; VALSPODAR;

ANIMAL CELL; APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; CALCULATION; CELL STRAIN; CELL STRAIN CACO 2; CLINICAL PRACTICE; CONTROLLED STUDY; DNA TRANSFECTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG PENETRATION; DRUG TRANSPORT; GASTROENTEROLOGY; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; INTESTINE SECRETION; MONOLAYER CULTURE; NONHUMAN; PHARMACODYNAMICS; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CELL CULTURE TECHNIQUES; COLONIC NEOPLASMS; CROHN DISEASE; DRUG RESISTANCE, MULTIPLE; HUMANS; P-GLYCOPROTEIN; PERMEABILITY; PREDNISONE; TUMOR CELLS, CULTURED;

EID: 4644250429     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200409000-00012     Document Type: Article

References (47)

1. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979;77:847-869.
2. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249-266.
3. Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. Gastroenterology. 1998;115: 835-840.
4. Papi C, Luchetti R, Gili L, et al. Budesonide in the treatment of Crohn's disease: a meta-analysis. Aliment Pharmacol Ther. 2000;14:1419-1428.
5. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347: 417-429.
6. Farrell RJ, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology. 2000;118:279-288.
7. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol. 2003;43: 285-307.
8. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet. 2001; 40:159-168.
9. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics. Clinical implications. Clin Pharmacokinet. 2003;42:59-98.
10. Uhr M, Holsboer F, Muller MB. Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J Neuroendocrinol. 2002;14:753-759.
11. Farrell RJ, Menconi MJ, Keates AC, et al. P-Glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes. Aliment Pharmacol Ther. 2002;16: 1021-1031.
12. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999;104:147-153.
13. Fromm MF, Kim RB, Stein CM, et al. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation. 1999;99:552-557.
14. Jonsson G, Astrom A, Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos. 1995;23:137-142.
15. Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2001;40:723-751.
16. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev. 1997;27:161-170.
17. Schinkel AH, Wagenaar E, van Deemter L, et al. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995;96:1698-1705.
18. Fromm MF. Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest. 2003;33:6-9.
19. Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology. 1989;96:736-749.
20. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun. 1991;29:880-885.
21. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998;101:289-294.
22. Pauli-Magnus C, von Richter O, Burk O, et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000;293:376-382.
23. Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev. 2002;54:1295-1310.
24. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, et al. P-glycoprotein: from genomics to mechanism. Oncogene. 2003;22:7468-7485.
25. Borchard G, Cassara ML, Roemele PEH, et al. Transport and local metabolism of budesonide and fluticasone propionate in a human bronchial epithelial cell line (Calu-3). J Pharm Sci. 2002;91:1561-1567.
26. Oka A, Oda M, Saitoh H. Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells. Biol Pharm Bull. 2002; 25:393-396.
27. Saitoh H, Hatakeyama M, Eguchi O, et al. Involvement of intestinal P-glycoprotein in the restricted absorption of methylprednisolone from rat small intestine. J Pharm Sci. 1998;87:73-75.
28. Karssen AM, Meijer OC, van der Sandt ICJ, et al. The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol. 2002;175:251-260.
29. Koszdin KL, Shen DD, Bernards CM. Spinal cord bioavailability of methylprednisolone after intravenous and intrathecal administration. The role of P-glycoprotein. Anesthesiology, 2000;92:156-163.
30. Karssen AM, Meijer OC, van der Sandt ICJ, et al. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology. 2001;142:2686-2694.
31. Bourgeois S, Gruol DJ, Newby RF, et al. Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol Endocrinol. 1993;7:840-851.
32. Ueda K, Okamura N, Hirai M, et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 1992;267:24248-24252.
33. Hofer KN. Oral budesonide in the management of Crohn's disease. Ann Pharmacother. 2003;37:1457-1464.
34. Ferry JJ, Horvath AM, Bekersky I, et al. Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. J Clin Pharmacol. 1988;28:81-87.
35. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13-33.
36. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug resistance gone: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473-3478.
37. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994;35:360-362.
38. Zheng H, Webber S, Zeevi A, et al. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol. 2002;63:765-770.
39. Farrell RJ, Kelleher D. Mechanisms of steroid action and resistance in inflammation. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol. 2003;178:339-346.
40. Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut. 2003;52:759-766.
41. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol. 1998;161:5733-5744.
42. Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology. 2003;124:26-33.
43. Brant SR, Panhuysen CI, Nicolae D, et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet. 2003; 73:1282-1292.
44. Mouly S, Paine MF. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res. 2003;20:1595-1599.
45. Fojo AT, Ueda K, Slamon DJ, et al. Expression of multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA. 1987;84:265-269.
46. Fricker G, Drewe J, Huwyler J, et al. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol. 1996;118:1841-1847.
47. Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther. 1997;283:1552-1562.